Table 1.
Study population characteristics and details of antiepileptic drug therapy
| Total pregnancies, n | 115 |
| Mean patient age (range), years | 30.3 (15–43) |
| Mean patient gravida (range) | 1.85 (1–6) |
| Racial distribution, n (% of total) | |
| Caucasian | 89 (77) |
| African-American | 19 (17) |
| Asian | 7 (6) |
| Epilepsy diagnosis, n (% of total) | |
| Localization-related epilepsy | 72 (63) |
| Generalized epilepsy | 37 (32) |
| Juvenile myoclonic epilepsy | 17 (15) |
| Childhood absence epilepsy | 4 (3) |
| Juvenile absence epilepsy | 4 (3) |
| Generalized epilepsy, unspecified | 12 (10) |
| Epilepsy, type unknown | 6 (5) |
| Antiepileptic drug, n | |
| Total | Monotherapy | Polytherapy | |
|---|---|---|---|
| Lamotrigine | 80 | 69 | 11 |
| Levetiracetam | 27 | 15 | 12 |
| Carbamazepine | 7 | 6 | 1 |
| Topiramate | 7 | 3 | 4 |
| Oxcarbazepine | 4 | 2 | 2 |
| Phenytoin | 2 | 1 | 1 |
| Valproate | 2 | 1 | 1 |
| Zonisamide | 2 | 1 | 1 |
| Ethosuximide | 1 | 1 | 0 |